Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 341

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 341
---
 shares of common stock are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

| A. | a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole                                                             
 business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or |

| B. | a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each 
 beneficiary of the trust is an individual who is an accredited investor,                                     |

securities or securities-based derivatives contract (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the common stock pursuant to an offer made under Section 275 of the SFA except:

| A. | to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any 
 person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;      |

| B. | where no consideration is or will be given for the transfer; |

| C. | as specified in Section 276(7) of the SFA; or |

| D. | as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities 
 based Derivatives Contracts) Regulations 2018.                                                                  |

233

Singapore SFA Product Classification — Solely for the purposes of its obligations
pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, the company has determined, and hereby notifies all relevant persons (as defined in Section 309A of the SFA) that the shares of common stock are “prescribed capital markets
products” (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment
Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

Notice to Prospective Investors in Switzerland

The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX
Sw